SCHEMBL3367326

SCHEMBL3367326

Cc1ccc(S(=O)(=O)N2CCCC2c2nnc(-c3cccs3)o2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.53
SMN1; SMN2 Q16637 3/20 0.53
TP53 P04637 3/20 0.53
MEN1 O00255 2/20 0.53
ALOX15 P16050 2/20 0.53
HTT P42858 2/20 0.53
KMT2A Q03164 2/20 0.53
TDP1 Q9NUW8 2/20 0.53
TSHR P16473 2/20 0.53
USP2 O75604 1/20 0.53
LMNA P02545 3/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
GAA P10253 2/20 0.48
ALDH1A1 P00352 4/20 0.48
THRB P10828 1/20 0.48
PSMD14 O00487 1/20 0.48
RAB9A P51151 2/20 0.46
NPC1 O15118 1/20 0.46
NFKB1 P19838 1/20 0.46
NFKB2 Q00653 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3367330 0.87 SMN1; SMN2 (0.49) KDM4ESMN1; SMN2TP53MEN1ALOX15
SCHEMBL3370573 0.83 MAPT (0.55) SMN1; SMN2TP53TDP1LMNAGAA
SCHEMBL3366618 0.80 SMN1; SMN2 (0.41) KDM4ESMN1; SMN2TP53MEN1ALOX15
SCHEMBL3366695 0.80 GAA (0.48) TP53MEN1KMT2ALMNAL3MBTL1
SCHEMBL3367393 0.79 MAPT (0.51) KDM4ESMN1; SMN2TP53KMT2ATSHR
SCHEMBL6177256 0.77 LMNA (0.79) SMN1; SMN2TSHRLMNAL3MBTL1GAA
SCHEMBL6177254 0.77 LMNA (0.79) SMN1; SMN2TSHRLMNAL3MBTL1GAA
SCHEMBL6068971 0.72 HTT (0.51) KDM4ESMN1; SMN2TP53MEN1ALOX15
SCHEMBL3367323 0.72 MAPK1 (0.39) KDM4ESMN1; SMN2TP53MEN1ALOX15
SCHEMBL3369463 0.71 ALDH1A1 (0.53) KDM4ESMN1; SMN2TP53MEN1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1532141-B1 2-PYRROLIDIN-2-YL- [1,3,4]-OXADIAZOLE DERIVATIVES AND THE USE OF THE SAME AS ANTIDEPRESSANTS GRUENENTHAL GMBH (DE) 2010-10-13 EP disclosed
US-7105538-B2 2-pyrrolidin-2-yl-[1,3,4]-oxadiazole compounds and their use as anti-depressants GRUENENTHAL GMBH (DE) 2006-09-12 US disclosed
US-20050187260-A1 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazole compounds and their use as anti-depressants GRUENENTHAL GMBH (DE) 2005-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187260-A1 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazole compounds and their use as anti-depressants OPRD1, OPRK1, GRIN2C KDM4E 1219/4885SMN1; SMN2 1832/4885TP53 4832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.